Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine

dc.contributor.author	Erguven, Mine
dc.contributor.author	Bilir, Ayhan
dc.contributor.author	Yazihan, Nuray
dc.contributor.author	Korkmaz, Seval
dc.contributor.author	Aktas, Esin
dc.contributor.author	Ovalioglu, Cem
dc.contributor.author	Dundar, Tolga
dc.contributor.author	Seyithanoglu, Hakan
dc.date.accessioned	2021-12-21T08:47:52Z
dc.date.available	2021-12-21T08:47:52Z
dc.date.issued	2012
dc.identifier.issn	1792-1074
dc.identifier.issn	1792-1082
dc.identifier.uri	https://doi.org/10.3892/ol.2011.434
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2313
dc.description.abstract	The purpose of the present study was to overcome resistance to imatinib (IM) by combining it with roscovitine (ROSC) and to investigate whether or not midkine (MK) had an effect on this combination in the treatment of glioblastoma (GBL). Human T98 GBL cel
dc.description.sponsorship	Coordination Unit of Istanbul UniversityIstanbul University [T988/06102006]
dc.language.iso	English
dc.publisher	Spandıdos Publ Ltd
dc.rights	Green Published, gold
dc.title	Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine
dc.type	Article
dc.relation.journal	Oncology Letters
dc.identifier.issue	1
dc.identifier.startpage	200
dc.identifier.endpage	208
dc.identifier.volume	3
dc.identifier.doi	10.3892/ol.2011.434
dc.relation.issue	1
dc.relation.volume	3